REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

INTRODUCTION: Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but there is a lack of data regarding efficacy and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vauchier, Charles, Auclin, Edouard, Barthélémy, Philippe, Carril-Ajuria, Lucia, Ryckewaert, Thomas, Borchiellini, Delphine, Castel-Ajgal, Zahra, Bennamoun, Mostefa, Campedel, Luca, Thiery-Vuillemin, Antoine, Coquan, Elodie, Crouzet, Laurence, Berdah, Jean-François, Chevreau, Christine, Ratta, Raffaele, Fléchon, Aude, Lefort, Felix, Albiges, Laurence, Gross-Goupil, Marine, Vano, Yann-Alexandre, Thibault, Constance, Oudard, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881133/
https://www.ncbi.nlm.nih.gov/pubmed/35222642
http://dx.doi.org/10.1155/2022/3449660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881133/
https://www.ncbi.nlm.nih.gov/pubmed/35222642
http://dx.doi.org/10.1155/2022/3449660

Ejemplares similares